| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2107007 | Cancer Cell | 2013 | 15 Pages |
SummaryOncogenic Kras activates a plethora of signaling pathways, but our understanding of critical Ras effectors is still very limited. We show that cell-autonomous phosphoinositide 3-kinase (PI3K) and 3-phosphoinositide-dependent protein kinase 1 (PDK1), but not Craf, are key effectors of oncogenic Kras in the pancreas, mediating cell plasticity, acinar-to-ductal metaplasia (ADM), and pancreatic ductal adenocarcinoma (PDAC) formation. This contrasts with Kras-driven non-small cell lung cancer, where signaling via Craf, but not PDK1, is an essential tumor-initiating event. These in vivo genetic studies together with pharmacologic treatment studies in models of human ADM and PDAC demonstrate tissue-specific differences of oncogenic Kras signaling and define PI3K/PDK1 as a suitable target for therapeutic intervention specifically in PDAC.
► PI3K (p110αH1047R)-induced neoplasia phenocopies KrasG12D-driven ADM, PanINs, and PDAC ► Deletion of Pdk1 blocks KrasG12D-induced PDAC but not NSCLC ► Craf is dispensable for Kras-induced PanIN and PDAC development ► The PI3K/PDK1 pathway is a target for therapeutic intervention in Kras-driven PDAC
